证券日报网讯 2月13日，长春高新在互动平台回答投资者提问时表示，管理费用是包括职工薪酬、折旧 摊销、办公费等一系列费用，具体情况公司已经在定期报告中管理费用相关章节中详细列示，公司持续 建立、健全费用管控、决策机制和内控体系，努力保障资金合规使用。 （编辑 袁冠琳） ...

证券日报网讯 2月13日，长春高新在互动平台回答投资者提问时表示，医保谈判情况具体需以政府部门 相关政策要求及最终结果为准，暂无具体情况可以介绍。 （文章来源：证券日报） ...

证券日报网讯2月13日，长春高新（000661）在互动平台回答投资者提问时表示，经营业绩请关注公司 定期报告等。 ...

证券日报网讯2月13日，长春高新（000661）在互动平台回答投资者提问时表示，公司与丹麦ALK- AbellóA/S公司合作的为屋尘螨(HDM)变应原特异性免疫治疗产品；其中屋尘螨变应原制剂(安脱达)是一 款在已上市销售的皮下注射免疫治疗屋尘螨变应原制剂；尘螨变应原舌下片(ACARIZAX)为全球首款被 批准用于过敏性哮喘和过敏性鼻炎的舌下免疫治疗片剂，已获得欧美等多个国家和地区监管机构上市批 准，目前已在中国大湾区和海南博鳌乐城医疗先行区应用，并同步正在中国开展临床研究。其他疾病事 项建议咨询专业的医护人员。 ...

Core Viewpoint - Changchun High-tech, known as "Northeast Medicine King," is facing a dramatic decline in performance, with a projected net profit of only 150 million to 220 million yuan for 2025, representing a year-on-year drop of over 90%, marking the worst performance in nearly two decades [1][6]. The company reported a staggering quarterly loss of nearly 1 billion yuan in Q4, with a year-on-year increase in losses of approximately 360% to 390% [1][6]. Group 1: Dependency on Single Product - The core issue behind the sharp decline in Changchun High-tech's performance is its long-standing reliance on the growth hormone business, which has been the company's profit pillar [2][7]. The net profit from its subsidiary, Jinsai Pharmaceutical, was nearly equal to the company's overall net profit in 2022 and 2023, highlighting its over-dependence [2][7]. - The inclusion of the core product, long-acting growth hormone "Jinsai Zeng," in the national medical insurance directory by the end of 2025 led to a price drop of approximately 75% for its 9mg specification, significantly eroding profit margins [2][7]. - The growth hormone market has shifted from a monopoly to intense competition, with similar products from companies like Teva and Novo Nordisk entering the market, breaking Changchun High-tech's previous technical barriers and market monopoly [2][7]. Group 2: Challenges in Transition - Recognizing the risks of putting all eggs in one basket, Changchun High-tech has been actively promoting transformation and increasing R&D investment, with R&D expenses expected to account for 20% of revenue in 2024 and a 23% year-on-year increase in R&D investment in the first three quarters of 2025 [3][8]. - However, the long and risky cycle of innovative drug development means that new products, such as the gout drug "Jin Peixin" and the cancer anorexia treatment "Mei Shiya," generated less than 160 million yuan in sales in the first three quarters of 2025, contributing minimally to overall performance [3][8]. - The company's sales expenses have been rising, with a sales expense ratio of 38.38% in the first three quarters of 2025, reflecting the need for deeper market coverage for mature products and significant resource investment for new product market education [3][8]. Group 3: Future Outlook - Industry analysis indicates that Changchun High-tech is currently in a transitional phase characterized by the "old engine losing power and the new engine not yet reaching speed" [4][9]. The impact of price reductions from medical insurance will take time to digest, and new products face multiple barriers before becoming performance pillars [4][9]. - In the short term, the company's performance may continue to be under pressure due to uncertainties in innovative drug development, underwhelming new product sales, and changes in industry policies [4][9]. - However, from a long-term perspective, as the price system for growth hormones stabilizes and market penetration improves with the support of medical insurance, this business may still provide a stable cash flow foundation for the company [4][9]. The ability to cultivate second and third growth curves through sustained high R&D investment will be crucial for Changchun High-tech to navigate the cycle and return to a growth trajectory [4][9].

Core Viewpoint - The simultaneous release of refinancing optimization measures by Shanghai, Shenzhen, and Beijing stock exchanges marks a significant transformation in China's capital market, aimed at enhancing capital allocation efficiency and reshaping the A-share market landscape [1]. Group 1: Policy Framework and Differences - The policy frameworks of the three exchanges are highly similar, focusing on "supporting the strong, limiting the weak, promoting innovation, and enhancing convenience and regulation" [2]. - Shanghai Stock Exchange emphasizes "main board" characteristics, tailoring financing rules for large, mature technology companies [2]. - Shenzhen Stock Exchange adopts a bolder stance on supporting technology innovation, easing fundraising restrictions for growth-oriented enterprises [2]. - Beijing Stock Exchange focuses on "innovative small and medium-sized enterprises," addressing their financing challenges with flexible policies [2]. Group 2: Strategic Insights on Separate Announcements - The decision to release policies on the same day rather than a joint announcement reflects the nuanced wisdom of tiered regulation in China's capital market [3]. - Different market positioning allows each exchange to cater to the unique characteristics and needs of the enterprises they serve, avoiding a one-size-fits-all approach [3]. - The simultaneous release creates a strong policy resonance, reinforcing market perception of deepening capital market reforms while maintaining the distinct identities of each exchange [3]. Group 3: Deep Impacts on Market Perception - The new measures aim to shift the long-standing fear of "blood-sucking" effects of refinancing, which was believed to drain market funds and destabilize the market [4]. - The principle of "supporting the strong, limiting the weak" will act as a catalyst for market differentiation, favoring quality companies, especially in hard technology, while raising barriers for poorly performing firms [4]. - The policy directs resources towards "new productive forces," providing strong support for leading companies in sectors like semiconductors, AI, biomedicine, and high-end manufacturing [5]. - Allowing companies that have experienced stock price declines to raise funds through methods like private placements and convertible bonds offers a lifeline to solid businesses facing temporary challenges [6]. - A complete regulatory loop is established, tightening post-fundraising supervision while relaxing initial approvals, transforming refinancing from a mere "money-raising tool" to an "engine" for corporate development [7]. Group 4: Implications for Investors - The coordinated actions of the three exchanges signify the entry of China's refinancing mechanism into a "precise drip irrigation" era, providing tailored financing support for different types of enterprises [8]. - Investors are advised to focus on genuinely innovative and well-governed companies while avoiding those that merely chase trends without substance [8]. - The transformation of refinancing from a "blood-sucking machine" to a "blood-producing pump" is expected to enhance the value discovery function of the A-share market, leading to a healthier and more vibrant capital market [8].

Group 1 - Fangda Carbon plans to acquire 100% equity of Tianjin Tongda Huanyu Logistics Co., Ltd. for 319 million yuan [1] - Xiamen Tungsten intends to acquire 39% equity of Jiujiang Dadi Mining Development Co., Ltd. and has signed an intention agreement with a transferor [6] - Wenkai Co. has won a bid for a landscape project worth 50.8162 million yuan [7] Group 2 - Changchun High-tech's subsidiary Jin Sai Pharmaceutical received approval for a clinical trial application for GenSci136, a treatment for IgA nephropathy [3] - China National Pharmaceutical has received drug registration certificates for fumaric acid volnoral tablets, used for treating reflux esophagitis [12] - Zhenhua Group plans to issue convertible bonds not exceeding 1.2 billion yuan [26] Group 3 - CSG Holding's stock may undergo a control change due to share pledge judicial transfer [30] - Ningbo Yunsheng plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [19] - Keda Guochuang's controlling shareholder intends to transfer 5% of the company's shares through an agreement [28] Group 4 - A number of companies, including Finer Pharma, Yixing Guoyuan Investment, and others, have announced plans to reduce their shareholdings by various percentages [2][4][9][11][15][16][20][21][22][23][25][29] - Highweida plans to repurchase shares worth 30 to 35 million yuan [17] - ST Zhongzhu is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [24] Group 5 - A number of companies, including Jiekang Equipment and others, have faced legal issues or penalties [27][40] - Aclaris Therapeutics has clarified that reports regarding its robotic products entering mass production were misinterpreted [41]

Core Viewpoint - The company, Changchun High-tech Industry (Group) Co., Ltd., announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial application of the injectable GenSci136 drug, which is intended for the treatment of Immunoglobulin A Nephropathy (IgAN) [1][2]. Group 1: Drug Information - The product name is injectable GenSci136, and it is a Class 1 biological product developed by Jinsai Pharmaceutical for the treatment of IgAN [1]. - The clinical trial application was approved under acceptance number CXSL2600033, allowing the drug to proceed with clinical trials [1]. Group 2: Disease Context - IgAN is the most common primary glomerulonephritis globally and accounts for 39.73% of primary glomerulonephritis cases in China, primarily affecting individuals aged 30 to 40 [2]. - The disease progresses slowly but has a poor prognosis, with 20%-50% of patients eventually progressing to renal failure, posing a significant burden on families and the healthcare system [2]. - There is a substantial unmet clinical need for effective treatments for IgAN, as existing therapies have limitations in efficacy and safety [2]. Group 3: Drug Mechanism and Potential - Injectable GenSci136 is designed as a B-cell maturation antigen (BCMA) trimeric fusion protein, which enhances the blocking activity against endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells [3]. - The drug aims to provide a new, safe, and effective first-line targeted treatment option for IgAN patients, with the potential for long-term application without the need for preventive anti-infection treatment [3].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed drug, GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - GenSci136 is a class 1 therapeutic biological product designed to treat IgAN, showcasing the company's commitment to innovative drug development [1] - The drug is a B-cell maturation antigen (BCMA) trimeric fusion protein, which utilizes novel molecular design to enhance the blocking activity against endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells [1] - GenSci136 is expected to provide a new, safe, and effective first-line targeted treatment option for IgAN patients, significantly improving their long-term prognosis [1] Group 2 - The design of GenSci136 includes an anti-human serum albumin heavy chain single-domain antibody to extend its half-life in the body, suggesting a potential for efficient and sustained therapeutic effects [1] - The drug aims to address various autoimmune diseases caused by pathogenic antibodies, indicating its broader therapeutic potential beyond IgAN [1] - The approval of the clinical trial marks a significant milestone for the company, reflecting its ongoing efforts in advancing biopharmaceutical innovations [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of its self-developed drug, GenSci136, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - GenSci136 is a class 1 therapeutic biological product designed to treat IgAN, showcasing innovative molecular design that mimics the natural extracellular domain of B-cell maturation antigen (BCMA) [1] - The drug enhances the blocking activity against various endogenous ligands, potentially impacting the survival and differentiation of B lymphocytes and plasma cells, thus addressing multiple autoimmune diseases caused by pathogenic antibodies [1] - GenSci136 is engineered with an anti-human serum albumin heavy chain single-domain antibody to extend its half-life in the body, suggesting a potential for effective and long-lasting treatment with improved convenience for patients [1] Group 2 - The drug is expected to provide a new, safe, and long-term targeted treatment option for IgAN patients without the need for prophylactic anti-infection therapy, aiming to significantly improve the long-term prognosis of these patients [1]